Topics

Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer http://bit.ly/2r3uclB  #pharmapic.twitter.com/qDPMf1wBLb

05:40 EST 4 Dec 2019 | Pharmafile

Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer http://bit.ly/2r3uclB 

Original Article: Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer http://bit.ly/2r3uclB  #pharmapic.twitter.com/qDPMf1wBLb

NEXT ARTICLE

More From BioPortfolio on "Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer http://bit.ly/2r3uclB  #pharmapic.twitter.com/qDPMf1wBLb"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...